Elijah Nouvelage/Bloomberg via Getty Images(NEW YORK) A new vaccine being studied in early clinical trials may hold the potential to help some women with breast cancer, a disease that affects one in every eight women in the United States, according to the Centers for Disease Control and Prevention.
The vaccine, which has not yet been named, targets triple-negative breast cancer, the most aggressive and deadliest form of breast cancer.
The vaccine s first clinical trial, the results of which were published last week, found that the vaccine caused no significant side effects and achieved a good immune response in 75% of patients in the trial.
The Phase 1 trial was composed of 16 women who received three vaccinations administered once every two weeks, according to Anixa Biosciences, Inc., the California-based company that is developing the vaccine.
The trial was conducted at the Cleveland Clinic and was supported by a grant from the U.S. Department of Defense, according to Anixa.
&